CorMedix (CRMD) Equity Ratio (2010 - 2025)

CorMedix has disclosed Equity Ratio across 15 years of filings, most recently posting 0.49 for Q4 2025.

• Equity Ratio for Q4 2025 came in at 0.49, down 31.13% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.49 (down 31.13% YoY), and the FY2025 annual result was 0.49, down 31.13% from the prior year.
• Equity Ratio came in at 0.49 for Q4 2025 at CorMedix, down from 0.5 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.95 in Q1 2021 to a low of 0.49 in Q4 2025.
• The 5-year median for Equity Ratio is 0.88 (2022), against an average of 0.83.
• Peak annual rise in Equity Ratio reached 24.41% in 2021, while the deepest fall reached 88.26% in 2021.
• CorMedix's Equity Ratio stood at 0.91 in 2021, then declined by 2.56% to 0.89 in 2022, then decreased by 3.69% to 0.85 in 2023, then fell by 16.66% to 0.71 in 2024, then tumbled by 31.13% to 0.49 in 2025.
• The last three Equity Ratio figures came in at 0.49 (Q4 2025), 0.5 (Q3 2025), and 0.87 (Q2 2025), per Business Quant data.